Market closed
Relay Therapeutics/$RLAY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Ticker
$RLAY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
304
Website
RLAY Metrics
BasicAdvanced
$1B
Market cap
-
P/E ratio
-$2.53
EPS
1.66
Beta
-
Dividend rate
Price and volume
Market cap
$1B
Beta
1.66
52-week high
$12.14
52-week low
$5.60
Average daily volume
1.5M
Financial strength
Current ratio
15.636
Quick ratio
15.284
Long term debt to equity
6.713
Total debt to equity
7.495
Management effectiveness
Return on assets (TTM)
-26.91%
Return on equity (TTM)
-43.28%
Valuation
Price to revenue (TTM)
22.676
Price to book
1.22
Price to tangible book (TTM)
1.23
Price to free cash flow (TTM)
-2.819
Growth
Revenue change (TTM)
3,637.58%
Earnings per share change (TTM)
-12.87%
3-year revenue growth (CAGR)
-25.30%
3-year earnings per share growth (CAGR)
-19.32%
What the Analysts think about RLAY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
RLAY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RLAY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RLAY News
AllArticlesVideos
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
GlobeNewsWire·2 days ago
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
GlobeNewsWire·1 week ago
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Relay Therapeutics stock?
Relay Therapeutics (RLAY) has a market cap of $1B as of November 08, 2024.
What is the P/E ratio for Relay Therapeutics stock?
The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of November 08, 2024.
Does Relay Therapeutics stock pay dividends?
No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Relay Therapeutics dividend payment date?
Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.
What is the beta indicator for Relay Therapeutics?
Relay Therapeutics (RLAY) has a beta rating of 1.66. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.